All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Did you miss ASH 2020? The GvHD Hub attended the 62nd ASH Annual Meeting & Exposition, December 5-8 2020, and has developed a downloadable resource on the practice-changing abstracts in graft-versus-host disease (GvHD).
In this updated resource, you will find comments from the GvHD Hub Steering Committee members on novel treatments, ruxolitinib and belumosudil for steroid-refractory chronic GvHD.
ASH 2020 | Practice-changing abstracts in graft-versus-host disease
If you would like to view the practice-changing abstracts from ASH 2020 and the expert opinions from our Steering Committee, please download the resource belowDownload Here
FDA accepts a supplemental new drug application for ruxolitinib in steroid-refractory cGvHD
On February 22, 2021, the U.S. Food and Drug Administration (FDA) granted priority review to a supplemental new drug application (sNDA) for ruxolitinib for...
Editorial theme | Latest updates on cGvHD treatment
First-line treatment for chronic graft-versus-host disease (cGvHD), which consists of steroids, has not changed much over the last three decades. In the case of severe cGvHD, another...
Subscribe to get the best content related to GvHD delivered to your inbox